Ask HopeStage to review this study with me
Study ID: NCT06194799. We help you review the study, but cannot decide medical eligibility.
Enrolling By InvitationNCT06194799
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
This study is enrolling by invitation. It focuses on schizophrenia and currently lists participation information in Brazil, Bulgaria, Chile, Czech Republic, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan, and the United States.
SchizophreniaDrugFrom 55 Years to 95 Years
Key information made simple
What is this study testing?
This study is testing whether a study medication may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive a study medication, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in Brazil, Bulgaria, Chile.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a hospital, with sites including ATP Clinical Research in Costa Mesa, Neuro-Pain Medical Center in Fresno, and New Life Medical Research Center in Hialeah. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually being able to understand the study and consent and meeting the main study requirements, while common reasons not to take part include other treatments that could interfere with the study and other factors that could make participation unsuitable. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: April 23, 2024
- Recruitment status
- Enrolling By Invitation
- Estimated enrollment
- Not clearly listed
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States, France, Brazil, ...
- Age range
- From 55 Years to 95 Years
- Official registry ID
- NCT06194799
- Official title
- ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT06194799. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Brazil.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 55 Years to 95 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by ACADIA Pharmaceuticals Inc., which appears to be another type of organization. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The recruitment status is not clearly listed. Check the official registry or contact the study team.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
Enrolling By InvitationNCT04987229
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
This study is enrolling by invitation. It focuses on schizophrenia and currently lists participation information in Argentina, Brazil, Colombia, Mexico, and the United States.
Enrolling By InvitationNCT07095465
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
This study is enrolling by invitation in the United States, in Bulgaria, and in Czech Republic. It is testing ACP-204 for Schizophrenia.
Enrolling By InvitationNCT05619822
A Comprehensive Third-generation Intervention for People With Psychosis and Post-traumatic Stress Symptoms
This study is enrolling by invitation. It focuses on schizophrenia and currently lists participation information in Spain.